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Abstract
Background: Oncogenous osteomalacia (OOM), which is also known as tumour-induced osteomalacia, is a rare
condition associated with a neoplasm and a related systemic bone demineralization caused by renal phosphate
wasting. OOM usually occurs in association with a variety of different mesenchymal tumours, and they were
categorized into four distinct morphological patterns which they termed “phosphaturic mesenchymal tumour”.O f
its 4 histopathological subtypes, the mixed connective tissue variant is most commonly observed. Only 10% of
cases appear in the head and neck regions and moreover, only 5 previously published tumors were localized in
the sinonasal area. The authors describe a case of a man with a PMT originating from the frontoethmoidal region.
Case presentation: A 53-year-old man was referred to our ORL clinic due to a presence of a mass at the nasal
root having been growing asymptomatically for 1 year. CT scans demonstrated a large (25 × 20 × 35 mm) bilateral
frontoethmoidal mass with destruction of nasal bones. The tumor did not appear to invade to the anterior skull
base. A selective angiography revealed a moderate hypervascularization of the tumour during early and late arterial
phases. The tumour was removed from the external approach and the definitive histopathological diagnosis was a
phospaturic mesenchymal tumor. Dual energy X-ray absorptiometry revealed a slight osteopenia of the first and
second lumbar vertebrae and neck of the thigh bone. The serum and urinary levels of both calcium and anorganic
phosphate were within normal limits. The patient is doing well three years after the operation, and the serum and
urine levels of calcium and phosphate remain well within normal limits.
Conclusion: PMT is rare in the sinonasal region, it can be rarely observed without the signs of osteomalacia.
Introduction
Oncogenous osteomalacia (OOM), which is also known
as tumour-induced osteomalacia, is a rare condition
associated with a neoplasm and a related systemic bone
demineralization caused by renal phosphate wasting
[1,2]. In 1947, unaware of the causative relation between
phosphate wasting and this neoplasm, McCance pub-
lished the first case [1]. OOM usually occurs in associa-
tion with a variety of different tumour types, frequently
very small, a fact which makes their discovery difficult
[2-4]. Most published cases were presented by various
soft tissue, bone neoplasms, and pseudotumors [4,5]. In
1987 Weidner and Santa Cruz revealed that many of
these mesenchymal tumours were histologically poly-
morphous, and they were categorized into four distinct
morphological patterns which they termed “phosphatu-
ric mesenchymal tumour” (PMT), comprising four sub-
types [4]. The most common one was a mixed
connective tissue variant (MCT), composed of primitive
mesenchymal cells. Quite recently, Folpe and colleagues
have reviewed 32 personal and 109 reported mesenchy-
mal OO-associated tumors, the latter representing the
majority of all published (English literature) cases [5].
102 out of the total of 141 various mesenchymal tumors
were reclassified as true or probable phosphaturic
mesenchymal tumor mixed connective tissue variant
(PMTMCT) and the above-mentioned three other var-
iants of PMT. Only 5 previously published tumors were
localized in the sinonasal area [5].
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oblivious to the existence of PMTMCT. Here, the case
of a 53-year-old man with a PMTMCT, originating
bilaterally from the frontoethmoidal region, is described.
Case Report
A 53-year-old man was referred to our ORL clinic due to
a presence of a mass at the nasal root having been grow-
ing asymptomatically for 1 year. The patient’s past medi-
cal history was unremarkable. The root of the nose was
enlarged by a non-tender, firm, ovoid mass, the overlay-
ing skin was intact. Nasal endoscopy revealed a smooth
bulge in the superior turbinate apparent on both sides.
An endoscopic biopsy was performed, and was accompa-
nied by profuse bleeding. The tentative histopathological
diagnosis was a juvenile angiofibroma. A computed
tomography (CT) scan demonstrated a large (25 × 20 ×
35 mm) bilateral frontoethmoidal, strongly enhancing (90
HU) mass with concomitant destruction of nasal bones,
the frontal processes of the maxilla, inferior wall of the
frontal sinuses and medial orbital wall. MRI scans
demonstrated that the tumour did not appear to invade
the anterior skull base [Figure 1, 2]. A selective bilateral
carotid angiography revealed a moderate hypervasculari-
zation (tortuous arteries) of the tumour during early and
late arterial phases. The hypervascular area was supplied
from internal and external carotid arteries through the
ophthalmic and maxillary arteries. In the parenchymatous
phase, a moderate tumour blush was visible. Dual energy
X-ray absorptiometry revealed a slight osteopenia of the
first and second lumbar vertebrae and neck of the thigh
bone. The serum and urinary levels of both calcium and
anorganic phosphate were within normal limits. Neither
the clinical picture nor all the above-mentioned findings
were consistent with osteomalacia.
The tumour was removed under general anesthesia.
After an H-shaped skin incision was made, we encoun-
tered a grayish-white mass invested in a thin capsule.
The tumour was easily extirpated from the intact pos-
terior wall of the frontal sinuses, anterior ethmoids,
and nasal cavity, and the posterosuperior part of the
nasal septum was also removed. The peroperative
bleeding was moderate, and it ceased immediately after
the tumour resection. The definitive histopathological
diagnosis was a PMTMCT variant [Figure 3]. It con-
sisted of benign (in appearance) undifferentiated
mesenchymal spindle- to stellate-shaped cells. The cells
were negative for CD 34, CD 99, S-100, AE1 and AE3.
The examination for smooth-muscle actin was focally
positive, a strong immunoreactivity for vimentin was
noted. Osteoclast-like giant cells were not found. In
some parts of the tumour a chondroid and osteoid dif-
ferentiation was noticed, as was a moderate microvas-
culature comprised of capillary-sized vessels invested in
endothelial cells. Some vessels showed a staghorn
branching pattern. No mitoses, atypia, foci of necrosis
or bleeding were observed in the tumour during the
histology assessment.
Figure 1 T2W MRI sagittal scan. Well bordered tumorous masses
of the nasal cavity, heterogeneous, and more hyperintensive
structures, destruction of the surrounding skeleton, prominence of
the masses into the bases of frontal sinuses, the rest filled with
liquid. No intra-cranial growth - lamina interna of the frontal sinus
preserved - narrow hem with no signal.
Figure 2 Axial CT scan. Well bordered soft-tissue tumormasses of
a middle signal intensity with destruction of the nasal bones,
usuration or even destruction of the medial orbital wall. Broadened
nose root, prominence of the masses dorsally, up to the frontal
ethmoid sinuses, rear ethmoides and sphenoidal sinus of normalairy
character.
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after the operation the patient is doing well; there is no
evidence of the disease in either endoscopic or CT
examinations, and the serum and urine levels of calcium
and phosphate remain well within normal limits.
Discussion
Phosphaturic mesenchymal tumour (PMT) is representa-
tive of a very rare group of neoplasms, usually benign
[2,5,6]. PMT with the mixed connective tissue variant
(PMTMCT) is the most commonly observed, while the
remaining minority consists of the three other histopatho-
logical subtypes (an osteoblastoma-like tumour, a non-
ossifying fibroma-like tumour and an ossifying fibroma-
like tumour) [3,4]. They are distinguished from other
mesenchymal tumours by the expression of a number of
gene products, which are related to bone matrix forma-
tion, mineralisation and mineral ion transport [3,7].
These tumours may occur in almost any location;
sinonasal area is affected very rarely [1,2,5,7]. In the ret-
rospective analysis of 109 cases reported in the English
language literature, Folpe found only 12 PMTMCTs and
1 ossifying fibroma-like PMT (13%) localized in the
head and neck region [5]. Five of these 13 tumours
developed in the sinonasal area (Table 1) [6,8-10].
The mechanism of the tumour-induced osteomalacia
remained unclear for many years but all the evidence
pointed to a circulating phosphaturic agent [2,3,7,11].
Recently, it has been demonstrated that some OOM-
associated tumours, including PMTMCT, over express
fibroblast growth factor FGF-23, a protein, which inhi-
bits renal phosphate reabsorption by a mechanism dis-
tinct from that of other known phosphate homeostasis
hormones [2,3,11]. The precise role of FGF-23 in the
pathogenesis of OOM is uncertain, but most FGFs
are potent stimulators of angiogenesis in vitro and
in vivo [3].
There were neither clinical nor laboratory signs of
osteomalacia in our patient with the tumour, which met
unambiguously all histopathological criteria for a
PMTMCT. Similarly, Folpe et al in their study revealed
3 cases of PMCMCT without a known history of phos-
phaturia, which they had considered a non-phosphaturic
variant of this histopathologic entity [5]. They specu-
lated that in such cases the tumour either secreted inac-
tive or insufficient FGF-23, or even none whatsoever.
Another possible explanation could be the patient’s
capacity to compensate for the increased secretion of
this factor in another manner [5]. Unfortunately, since
the FGF-23 antibody is not commercially available, we
failed to test the above-described tumour for that factor.
In this respect, our case was not contributory. For
Figure 3 A photomicrograph showing numerous small
mesenchymal cells, vascular channels, and osteoid areas
(asterisk) (H & E, 10×). Inset: chondroid differentiation of the
stroma (H & E, 200×)
Table 1 A review of sinonasal PMT MCT
Author Sex, age Location Therapy Follow-up interval/tumour/signs
of OO
Koriyama [2] F, 41y max. sinus surgical not indicated
Weidner [4] F, 39 y max. sinus, infratemporal fossa invasion, right surgical removal 27 mo/recurrence/present
Gonzales [6] F, 69 y max. and frontal sinus, ethmoids, intracranial invasion, right none died of tumor-related reasons
Linsey [8] F, 54 y nasopharynx surgical removal not indicated
Papotti [9] F, 38 y max. sinus, ethmoids, nasal cavity, orbital floor invasion, left radiotherapy part.
surg. removal
18 mo/not indicated/present
Kawai [10] F, 53 y nasal cavity, ethmoids, right surgical removal not indicated
present case M, 53 y frontal sinus, ethmoids, nasal cavity billat surgical removal 24 mo/no evidence of tumor/
primarily not present
OO - oncogenous osteomalacia
mo - months
F - female
M - male
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PMTMCT, FGF-23 immunohistochemistry is not
crucial.
PMTMCT is basically a benign lesion, histologically
malignant, metastasizing variants of which happen to
occur extremely rarely [5,7]. Nonetheless, infiltration
and invasion of surrounding tissues are very frequent
features of this otherwise benign-appearing PMTMCT
[3,5].
In general, a reasonable treatment protocol for PMT
MTC is a complete surgical removal, which dramatically
resolves the tumour-associated osteomalacia (known for
its resistance to conservative therapy). Owing to its local
invasiveness, the lesion should be removed using wide
margins of resection [2,5-7]. Remnants of the tumour
may be inadvertently left behind, threatening the patient
with serious local and systemic complications resulting
from continuous growth and renal phosphate wasting,
respectively [5]. A postoperative laboratory and radiolo-
gical follow-up is thus necessary [2].
Conclusion
In most patients with oncogenous osteomalacia, the cau-
sative tumour is a PMTMCT. About 5% of all these
lesions originate in the frontoethmoidal area. Here, the
tumour may easily go unrecognized until a thorough
battery of CT scans is performed. Local invasion is a
characteristic feature of benign PMTMCT, requiring
wide-margin resection. Given the spatial limitations
imposed by surrounding anatomical structures, residual
tumour may be left behind in that area, making careful
follow-ups an absolute necessity.
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